Using macrophage activation to augment immunotherapy of established tumours

Keyphrases

• Tumor 100%
• Tumor Microenvironment 100%
• Tumor-associated Macrophages 100%
• Macrophage Activation 100%
• DMXAA 80%
• Intratumoural 60%
• Macrophages 40%
• Macrophage Phenotype 40%
• Lung Cancer 20%
• Quantitative PCR 20%
• Flow Cytometry 20%
• Neutrophils 20%
• Myeloid Cells 20%
• Antitumor 20%
• CD8+ T Cells 20%
• Murine Model 20%
• Cell Phenotype 20%
• Ability to Change 20%
• Therapeutic Effect 20%
• Antigen Specificity 20%
• Immune Suppression 20%
• Antitumor Immune Response 20%
• Active Immunization 20%
• Macrophage Depletion 20%
• M2 Macrophages 20%
• 5,6-dimethylxanthenone-4-acetic Acid 20%
• Vadimezan 20%
• M1 Macrophages 20%
• Antitumor Efficacy 20%
• Immune Cell Phenotypes 20%

Immunology and Microbiology

• Immunotherapy 100%
• Macrophage Activation 100%
• Tumor-Associated Macrophage 77%
• Macrophage 22%
• Myeloid 11%
• Neutrophil 11%
• Cytotoxic T-Cell 11%
• Immunocompetent Cell 11%
• Immune Response 11%
• Antigen Specificity 11%
• Active Immunotherapy 11%
• Reverse Transcription Polymerase Chain Reaction 11%
• Acetate 11%
• Lung 11%
• M1 Macrophage 11%